A phase I study of dovitinib (TKI258) in Japanese patients with advanced solid tumors.

Hiroya Takiuchi,Masahiro Gotoh,Motoki Yoshida,Takayuki Kii,Keishi Yamashita,Yu Sunakawa,Toshikado Kaneta,Matthew Robson,Tomoyuki Kakizume,Yasutsuna Sasaki

A phase I study of dovitinib (TKI258) in Japanese patients with advanced solid tumors.

2017

Hiroya Takiuchi
Masahiro Gotoh
Motoki Yoshida
Takayuki Kii
Keishi Yamashita
Yu Sunakawa
Toshikado Kaneta
Matthew Robson
Tomoyuki Kakizume
Yasutsuna Sasaki

3088^ Background: Dovitinib is a tyrosine kinase inhibitor with demonstrated inhibitory activity against FGFRs, VEGFRs, and PDGFRs in vivo. Based on responses observed in renal cell carcinoma, brea...

Keywords:

Pathology
Tyrosine-kinase inhibitor
Inhibitory postsynaptic potential
Cancer research
In vivo
Medicine
Renal cell carcinoma
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations